Roche’s $2.3 Billion Nurix Deal Sends Shares Moving
This article first appeared on GuruFocus. Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NASDAQ:NRIX) as…
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
Around 200 patients a year will benefit from consolidating the routine use of two marketed drugs for NHS…
Roche to pay Nurix as much as US$2.3 bil in cancer drug deal
The collaboration adds to Roche’s push to bolster its cancer portfolio, as it seeks new drivers of growth…
Roche and Nurix strike $2.3 billion blood cancer drug deal
Roche entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an…
Managing Quality of Life with CML
Understanding chronic myeloid leukemia Chronic myeloid leukaemia (CML) is a type of cancer that develops in the blood-forming…